Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 408

The DOI matches its Crossref record; 114 of the 114 references it cites were found in a registry or an index.

Inhibition of LFA‐1/ICAM‐1 and VLA‐4/VCAM‐1 as a therapeutic approach to inflammation and autoimmune diseases

Yusuf‐Makagiansar, Helena, Anderson, Meagan E., Yakovleva, Tatyana V., Murray, Joseph S., Siahaan, Teruna J.·2002·Medicinal Research Reviews

Abstract

This review focuses on providing insights into the structural basis and clinical relevance of LFA‐1 and VLA‐4 inhibition by peptides and small molecules as adhesion‐based therapeutic strategies for inflammation and autoimmune diseases. Interactions of cell adhesion molecules (CAM) play central roles in mediating immune and inflammatory responses. Leukocyte function‐associated antigen (LFA‐1, α L β 2, and CD11a/CD18) and very late antigen (VLA‐4, α 4 β 1, and CD49d/CD29) are members of integrin‐type CAM that are predominantly involved in leukocyte trafficking and extravasation. LFA‐1 is exclusively expressed on leukocytes and interacts with its ligands ICAM‐1, ‐2, and ‐3 to promote a variety of homotypic and heterotypic cell adhesion events required for normal and pathologic functions of the immune systems. VLA‐4 is expressed mainly on lymphocyte, monocytes, and eosinophils, but is not found on neutrophils. VLA‐4 interacts with its ligands VCAM‐1 and fibronectin (FN) CS1 during chronic inflammatory diseases, such as rheumatoid arthritis, asthma, psoriasis, transplant‐rejection, and allergy. Block‐ade of LFA‐1 and VLA‐4 interactions with their ligands is a potential target for immunosuppression. LFA‐1 and VLA‐4 antagonists (antibodies, peptides, and small molecules) are being developed for controlling inflammation and autoimmune diseases. The therapeutic intervention of mostly mAb‐based has been extensively studied. However, due to the challenging relative efficacy/safety ratio of mAb‐based therapy application, especially in terms of systemic administration and immunogenic potential, strategic alternatives in the forms of peptide, peptide mimetic inhibitors, and small molecule non‐peptide antagonists are being sought. Linear and cyclic peptides derived from the sequences of LFA‐1, ICAM‐1, ICAM‐2, VCAM‐1, and FN C1 have been shown to have inhibitory effects in vitro and in vivo. Finally, understanding the mechanism of LFA‐1 and VLA‐4 binding to their ligands has become a fundamental basis in developing therapeutic agents for inflammation and autoimmune diseases. © 2002 John Wiley& Sons, Inc. Med Res Rev, 22, No. 2, 146–167, 2002; DOI 10.1002/med.10001

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/med.10001

Cites

114 of 114 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 114 references

Research works printed but not linked: 51

  1. Gürsoy RN, 1997, Inhibition of ICAM‐1/LFA‐1 interactions for inducing immunotolerance, Curr Top Pept Prot Res, 2, 53
  2. 10.1126/science.285.5425.207 · doi:10.1126/science.285.5425.207
  3. Yusuf‐Makagiansar H, 2000, Modulation of adhesion molecules in lymphocyte activation and cell–cell interaction, Curr Top Biochem Res, 2, 33
  4. Giddings JC, 1999, Intercellular adhesion in vascular biology, thrombosis and cancer, Br J Biomed Sci, 56, 66
  5. 10.1111/j.1445-2197.1996.tb00752.x · doi:10.1111/j.1445-2197.1996.tb00752.x
  6. 10.3109/15419060009109020 · doi:10.3109/15419060009109020
  7. 10.1159/000179238 · doi:10.1159/000179238
  8. 10.1016/S0168-1702(99)00038-6 · doi:10.1016/s0168-1702(99)00038-6
  9. 10.1074/jbc.271.39.23920 · doi:10.1074/jbc.271.39.23920
  10. 10.1053/beha.1999.0050 · doi:10.1053/beha.1999.0050
  11. Nakajima S, 1995, A hierarchy for integrin expression and adhesiveness among T cell subsets that is linked to TCR gene usage and emphasizes Vd1 + gd T cell adherence and tissue retention, J Immunol, 155, 1117, 10.4049/jimmunol.155.3.1117 · doi:10.4049/jimmunol.155.3.1117
  12. 10.1002/eji.1830270106 · doi:10.1002/eji.1830270106
  13. 10.1111/j.1365-2249.1993.tb03413.x · doi:10.1111/j.1365-2249.1993.tb03413.x
  14. Clark CL, 1990, Lymphocyte infiltration patterns in rat small‐bowel transplants, Transplant Proc, 22, 2460
  15. 10.1006/cimm.1996.1050 · doi:10.1006/cimm.1996.1050
  16. 10.1016/S0165-2478(99)00133-9 · doi:10.1016/s0165-2478(99)00133-9
  17. 10.1016/S0198-8859(00)00101-4 · doi:10.1016/s0198-8859(00)00101-4
  18. 10.1038/ki.1997.202 · doi:10.1038/ki.1997.202
  19. 10.1136/jcp.49.3.238 · doi:10.1136/jcp.49.3.238
  20. 10.1016/S0002-9440(10)65296-0 · doi:10.1016/s0002-9440(10)65296-0
  21. 10.1073/pnas.93.10.4821 · doi:10.1073/pnas.93.10.4821
  22. 10.1097/00007890-199506150-00013 · doi:10.1097/00007890-199506150-00013
  23. Isobe M, 1994, Immunosuppression to cardiac allografts and soluble antigens by anti‐vascular cellular adhesion molecule‐1 and anti‐very late antigen‐4 monoclonal antibodies, J Immunol, 153, 5810, 10.4049/jimmunol.153.12.5810 · doi:10.4049/jimmunol.153.12.5810
  24. 10.1136/gut.47.1.97 · doi:10.1136/gut.47.1.97
  25. Molina A, 1994, Prevention of mercuric chloride‐induced nephritis in the brown Norway rat by treatment with antibodies against the α4 integrin, J Immunol, 153, 2313, 10.4049/jimmunol.153.5.2313 · doi:10.4049/jimmunol.153.5.2313
  26. 10.1074/jbc.M008967200 · doi:10.1074/jbc.m008967200
  27. Labadia ME, 1998, Molecular regulation of the interaction between leukocyte function‐associated antigen‐1 and soluble ICAM‐1 by divalent metal cations, J Immunol, 161, 836, 10.4049/jimmunol.161.2.836 · doi:10.4049/jimmunol.161.2.836
  28. 10.1084/jem.183.3.1247 · doi:10.1084/jem.183.3.1247
  29. 10.1016/S0167-5699(99)01467-X · doi:10.1016/s0167-5699(99)01467-x
  30. 10.1002/jlb.66.1.67 · doi:10.1002/jlb.66.1.67
  31. 10.1073/pnas.96.6.3017 · doi:10.1073/pnas.96.6.3017
  32. 10.1038/387312a0 · doi:10.1038/387312a0
  33. 10.1074/jbc.270.11.5979 · doi:10.1074/jbc.270.11.5979
  34. 10.1164/ajrccm.156.3.9609039 · doi:10.1164/ajrccm.156.3.9609039
  35. Vanderslice P, 1997, A cyclic hexapeptide is a potent antagonist of α4 integrins, J Immunol, 158, 1710, 10.4049/jimmunol.158.4.1710 · doi:10.4049/jimmunol.158.4.1710
  36. 10.1016/S0021-9258(18)54139-9 · doi:10.1016/s0021-9258(18)54139-9
  37. 10.1074/jbc.270.31.18401 · doi:10.1074/jbc.270.31.18401
  38. 10.1042/bj3270727 · doi:10.1042/bj3270727
  39. 10.1038/sj.bjp.0702511 · doi:10.1038/sj.bjp.0702511
  40. 10.1016/S0960-894X(00)00088-3 · doi:10.1016/s0960-894x(00)00088-3
  41. 10.1016/S0960-894X(00)00089-5 · doi:10.1016/s0960-894x(00)00089-5
  42. 10.1111/j.1399-3011.1999.tb01613.x · doi:10.1111/j.1399-3011.1999.tb01613.x
  43. 10.1080/07391102.1999.10508375 · doi:10.1080/07391102.1999.10508375
  44. 10.1016/S0196-9781(00)00255-2 · doi:10.1016/s0196-9781(00)00255-2
  45. 10.1089/aid.1993.9.733 · doi:10.1089/aid.1993.9.733
  46. 10.1016/0014-5793(91)80475-I · doi:10.1016/0014-5793(91)80475-i
  47. 10.1002/1099-1387(200008)6:8<398::AID-PSC270>3.0.CO;2-1 · doi:10.1002/1099-1387(200008)6:8<398::aid-psc270>3.0.co;2-1
  48. 10.1097/00007890-199803150-00017 · doi:10.1097/00007890-199803150-00017
  49. Gerli R, 1998, Salicylates inhibit adhesion and transmigration of T lymphocytes by preventing integrin activation induced by contact with endothelial cells, Blood, 92, 2389, 10.1182/blood.V92.7.2389 · doi:10.1182/blood.v92.7.2389
  50. 10.1002/1529-0131(199809)41:9<1677::AID-ART20>3.0.CO;2-4 · doi:10.1002/1529-0131(199809)41:9<1677::aid-art20>3.0.co;2-4
  51. 10.1006/excr.1994.1139 · doi:10.1006/excr.1994.1139

Cited by

See all 408

Metadata

Authors
Yusuf‐Makagiansar, H., Anderson, M. E., Yakovleva, T. V., Murray, J. S., & Siahaan, T. J.
Venue
Medicinal Research Reviews
Publisher
Wiley
Published
2002-02-08
Volume
22
Issue
2
Pages
146-167
ISSN
  • 0198-6325 (ISSN-L)
  • 1098-1128
OpenAlex
W2050681882
Cited by
408
References
114
FWCI
12.38
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inhibition of LFA‐1/ICAM‐1 and VLA‐4/VCAM‐1 as a therapeutic approach to inflammation and autoimmune diseases. https://app.cochat.ai/papers/10.1002/med.10001
The paper
Yusuf‐Makagiansar, H., Anderson, M. E., Yakovleva, T. V., Murray, J. S., & Siahaan, T. J. (2002). Inhibition of LFA‐1/ICAM‐1 and VLA‐4/VCAM‐1 as a therapeutic approach to inflammation and autoimmune diseases. Medicinal Research Reviews. https://doi.org/10.1002/med.10001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.